Genus Lifesciences Inc. received FDA approval on October 20, 2010, for OxyCODONE HYDROCHLORIDE (NDA200535), a move expected to bolster the generic market for this critical analgesic and increase pricing pressure in the branded opioid space. The addition of this oral formulation expands the manufacturer's portfolio and solidifies its presence within the increasingly competitive pain management sector.